| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/25/2004 | EP1390068A1 Methods and formulations of using a1 adenosine and p2x purinoreceptor antagonists |
| 02/25/2004 | EP1390063A2 Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| 02/25/2004 | EP1390057A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use |
| 02/25/2004 | EP1390051A2 Food compositions for reducing insulin resistance |
| 02/25/2004 | EP1390048A2 Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders |
| 02/25/2004 | EP1390047A1 Taste masking pharmaceutical composition |
| 02/25/2004 | EP1390046A2 Treatment of neoplasms with viruses |
| 02/25/2004 | EP1390045A1 The use of a compound with a negatively charged domain of radicals for the treatment of restenosis |
| 02/25/2004 | EP1390044A1 Injectable pamidronate disodium |
| 02/25/2004 | EP1390043A1 Means and method for hormonal contraception |
| 02/25/2004 | EP1390042A1 Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| 02/25/2004 | EP1390041A1 Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| 02/25/2004 | EP1390040A1 Pharmaceutical composition for use in hormone replacement therapy |
| 02/25/2004 | EP1390039A1 Use of estrogen compounds to increase libido in women |
| 02/25/2004 | EP1390038A2 Treatment of conditions relating to hormone deficiencies by administration of progestins |
| 02/25/2004 | EP1390037A1 Methods for treating delirium using glucocorticoid receptor-specific antagonists |
| 02/25/2004 | EP1390036A1 Prostanoic acid derivatives as agents for lowering intraocular pressure |
| 02/25/2004 | EP1390035A1 Method for treating ocular hypertension and glaucoma |
| 02/25/2004 | EP1390034A1 N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| 02/25/2004 | EP1390033A1 Farnesyl protein transferase inhibitors for treating cachexia |
| 02/25/2004 | EP1390032A2 Novel quaternary ammonium compositions coupled with facilitating anions and their use in kits, as well as their use in preventing and treating certain conditions |
| 02/25/2004 | EP1390031A2 Topical composition containing a fungicide |
| 02/25/2004 | EP1390030A1 Store operated calcium influx inhibitors and methods of use |
| 02/25/2004 | EP1390029A1 Phenylindoles for the treatment of hiv |
| 02/25/2004 | EP1390028A2 Use of lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy |
| 02/25/2004 | EP1390027A1 Composition comprising demethylcantharidin in combination with platinum-containing anticancer agents and use thereof |
| 02/25/2004 | EP1390026A1 Treatment of hpv caused diseases |
| 02/25/2004 | EP1390025A1 Coenzyme q and eicosapentaenoic acid (epa) |
| 02/25/2004 | EP1390024A1 Isostearic acid salts as permeation enhancers |
| 02/25/2004 | EP1390023A2 Pharmaceutical salts |
| 02/25/2004 | EP1390022A1 Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno 2,3-d]pyrimidine for the treatment of pain |
| 02/25/2004 | EP1390021A1 Delivery of compounds for the treatment of migraine through an inhalation route |
| 02/25/2004 | EP1390019A1 Controlled release drug delivery device |
| 02/25/2004 | EP1390018A1 A pharmaceutical tablet having a high api content |
| 02/25/2004 | EP1390015A1 Taste-masking of highly water-soluble drugs |
| 02/25/2004 | EP1390014A1 Composition and methods for treatment of hyperplasia |
| 02/25/2004 | EP1390011A2 Control of compactability through crystallization |
| 02/25/2004 | EP1390008A2 Pharmaceutical and cosmetic compositions against skin aging |
| 02/25/2004 | EP1389970A2 Compositions and methods of double-targeting virus infections and cancer cells |
| 02/25/2004 | EP1389911A1 Ectoparasiticidal compositions and methods of their use |
| 02/25/2004 | EP1389910A1 Intraoral delivery of nicotine for smoking cessation |
| 02/25/2004 | EP1389909A1 Antimicrobial compounds and methods for their use |
| 02/25/2004 | EP1301503B1 Coumarin derivatives with comt inhibiting activity |
| 02/25/2004 | EP1300407B1 Carbamates derived from arylalkylamines |
| 02/25/2004 | EP1292293B1 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| 02/25/2004 | EP1283837B1 New thiochromane derivatives and their use as thrombin inhibitors |
| 02/25/2004 | EP1267902B1 Cosmetic use of hop and ornithine |
| 02/25/2004 | EP1263756B1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 02/25/2004 | EP1239879B1 Formulations of adenosine a1 agonists and cox2-inhibitors |
| 02/25/2004 | EP1239878B1 Formulations of adenosine a1 agonists and 5ht1 agonists |
| 02/25/2004 | EP1235833B1 Analogs of (1s, cis)-4-(2-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral |
| 02/25/2004 | EP1232158B1 Anti-inflammatory oxo derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use |
| 02/25/2004 | EP1230232B1 Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 02/25/2004 | EP1230223B1 Oligobenzimidazole derivatives and their use as dna transfection agents |
| 02/25/2004 | EP1222171B1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 02/25/2004 | EP1220665B1 Hop acids used to inhibit staphylococcus aureus |
| 02/25/2004 | EP1210326B1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/25/2004 | EP1206469B1 Antibacterial heterobicyclic substituted phenyl oxazolidinones |
| 02/25/2004 | EP1206447B1 Selective inhibitors of the urokinase plasminogene activators |
| 02/25/2004 | EP1202739A4 Rapid immediate release oral dosage form |
| 02/25/2004 | EP1200443B1 Aromatic esters of camptothecins and methods to treat cancers |
| 02/25/2004 | EP1200409B1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 02/25/2004 | EP1181269B1 Cell proliferation inhibitors |
| 02/25/2004 | EP1178986B1 Furanone derivatives as inhibitors of cathepsin s |
| 02/25/2004 | EP1175203A4 Folic acid supplement |
| 02/25/2004 | EP1165064B1 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 02/25/2004 | EP1165049B1 Agglomerates by crystallisation |
| 02/25/2004 | EP1149067B1 7-aryl-6(z)heptatrienoic acid retinamides as apoptosis inducing compounds and their use as anti-cancer agents |
| 02/25/2004 | EP1140931B1 5ht1 antagonists for antidepressant therapy |
| 02/25/2004 | EP1138333B1 Medicinal compositions for oral use |
| 02/25/2004 | EP1135481B1 New oligomeric conjugates liable to transfer biological molecules into cells |
| 02/25/2004 | EP1128812B1 Nano-emulsion of 5-aminolevulinic acid |
| 02/25/2004 | EP1117392B1 Method for preventing or delaying catheter-based revascularization |
| 02/25/2004 | EP1087934B1 Aminocyclohexyl ether compounds and uses thereof |
| 02/25/2004 | EP1080090B1 Antitumour 1,5-diazaanthraquinones |
| 02/25/2004 | EP1042296B1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 02/25/2004 | EP1040108B1 Ortho-anthranilamide derivatives as anti-coagulants |
| 02/25/2004 | EP1039908B1 Molecular dispersion composition with enhanced bioavailability |
| 02/25/2004 | EP1037612B1 Pharmaceutical compositions containing micronized bicyclic drugs |
| 02/25/2004 | EP1037609B1 Aqueous insecticidal pour-on formulation |
| 02/25/2004 | EP1037607B1 Novel suppository form comprising an acid-labile active compound |
| 02/25/2004 | EP1032402B1 Use of citicoline for the treatment of multiple sclerosis (MS) |
| 02/25/2004 | EP1025114B1 3'-n-modified 6-o-substituted erythromycin ketolide derivatives having antibacterial activity |
| 02/25/2004 | EP1005446B1 N-aroylphenylalanine derivatives |
| 02/25/2004 | EP0988797B1 Use of compositions for postgastrectomic mineral supply |
| 02/25/2004 | EP0984967B1 Naphthyridine derivatives and their analogues inhibiting cytomegalovirus |
| 02/25/2004 | EP0981526B1 Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| 02/25/2004 | EP0965344B1 Prophylactic and therapeutic agent for inflammatory intestinal diseases |
| 02/25/2004 | EP0954336B1 Membrane incorporation of texaphyrins |
| 02/25/2004 | EP0946181B1 Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications |
| 02/25/2004 | EP0918756B1 Parasiticidal pyrazoles |
| 02/25/2004 | EP0906297B1 1,2,4-benzothiadiazine derivatives, their preparation and use |
| 02/25/2004 | EP0883405B1 Amidino protease inhibitors |
| 02/25/2004 | EP0873301B1 Indane compounds with smooth muscle relaxing and/or mast cell stabilising and/or anti-inflammatory activity |
| 02/25/2004 | EP0866861B1 Molecular cloning and characterization of molecules related to relaxin and the insulin family of ligands |
| 02/25/2004 | EP0831834B1 Debromohymenialdisine and related compounds for treating osteoarthritis |
| 02/25/2004 | EP0825853B1 Prolonged nerve blockage by the combination of local anesthetics and glucocorticoids |
| 02/25/2004 | EP0820515B1 Phospholipase c homolog |
| 02/25/2004 | EP0758897B1 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| 02/25/2004 | EP0751957B1 Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases |